1403474-75-8Relevant articles and documents
High-purity, small-particle-diameter and low-solvent-residue azilsartan bulk drug and preparation method thereof
-
, (2019/01/06)
The present invention discloses a high-purity, small-particle-diameter and low-solvent-residue azilsartan bulk drug and a preparation method thereof. The purity of the azilsartan bulk drug is more than or equal to 99.9%; the particle size of D90 is less than or equal to 20 [mu]m; and the solvent residue is less than or equal to 500 ppm. The present invention also discloses a high-purity intermediate used for preparing the azilsartan bulk drug and a preparation method thereof, wherein the purity of the intermediate is more than or equal to 99.9%.
Novel preparation method of azilsartan
-
, (2018/11/22)
The invention relates to a novel preparation method of azilsartan with relatively high yield and relatively high purity. A multi-refining or column chromatography method is not needed, in addition, the final yield reduction can not be caused. According to the preparation route provided by the application, the contents of an impurity A and an impurity B can be effectively reduced, the refining frequency is reduced, and the yield is also increased.
Aitch sand smooth intermediate and its preparation method (by machine translation)
-
, (2017/02/09)
The invention discloses Aitch sand smooth intermediate and its preparation method. The preparation method comprises the following steps: in the solvent, compound 2B with hydroxylamine mixing, reaction, get compound 3B can be. The invention method for preparing the Aitch of less impurity, short reaction time, the higher process yield, high purity of the product, is suitable for industrial production. (by machine translation)
Synthesis of azilsartan and its selected potential impurities
Radl, Stanislav,Cerny, Josef,Stach, Jan,Holec, Jan,Pisa, Ondrej,Gablikova, Zuzana
, p. 929 - 936 (2013/08/23)
Synthesis of angiotensin II AT1 receptor antagonist azilsartan is described. The results include reinvestigation of the described process as well as its novel modification. This new process includes transformation of the CN group into amidoxime moiety by aqueous hydroxylamine, its treatment with alkyl chloroformates and a base-initiated cyclization of the formed (alkoxycarbonyl-oxy)carbamimidoyl intermediates. Several so far undescribed side-products were identified and some of them were synthesized and duly characterized as potential impurities.